Vimarsana
Biggest News Aggregation in the World

Page 46 - Jack Weinstein News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jack Weinstein. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jack Weinstein Today - Breaking & Trending Today

Relief Therapeutics Reports Execution of Stipulation with NeuroRx and Jonathan Javitt to Continue Mediation Process - Vimarsana News

Relief Therapeutics Reports Execution of Stipulation with NeuroRx and Jonathan Javitt to Continue Mediation Process

Relief Therapeutics Holding SA / Key word(s): Legal Matter Relief Therapeutics Reports Execution of Stipulation with NeuroRx and Jonathan Javi...

Relief Therapeutics Announces that its Subsidiary was Issued a Swiss Patent Entitled 'Vasoactive Int - Vimarsana News

Relief Therapeutics Announces that its Subsidiary was Issued a Swiss Patent Entitled 'Vasoactive Int

Relief Therapeutics Holding SA / Key word(s): Patent01-Apr-2022 / 07:15 CET/CESTRelease of an ad hoc announcement pursuant to Art. 53 LRThe issuer is solely responsible for the content of this announcement.Relief Therapeutics Announces that its Subsidiary, AdVita Lifescience GmbH, was Issued a Swiss Patent Entitled...

Relief Therapeutics Announces that its Subsidiary was Issued a Swiss Patent Entitled 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis' - Vimarsana News

Relief Therapeutics Announces that its Subsidiary was Issued a Swiss Patent Entitled 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis'

Relief Therapeutics Holding SA / Key word(s): Patent Relief Therapeutics Announces that its Subsidiary was Issued a Swiss Patent Entitled 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis' 01-Apr-2022 / 07:15 CET/CEST Release of an ad hoc announcement ...

Relief Reports that its U.S. Collaboration Partner has Announced that the I-SPY COVID Trial Suggests No Clinical Benefit with Addition of Nebulized Aviptadil in Critically Ill Patients with COVID-19 - Vimarsana News

Relief Reports that its U.S. Collaboration Partner has Announced that the I-SPY COVID Trial Suggests No Clinical Benefit with Addition of Nebulized Aviptadil in Critically Ill Patients with COVID-19

Relief Therapeutics Holding SA / Key word(s): Study Relief Reports that its U.S. Collaboration Partner has Announced that the I-SPY COVID Trial Suggests No Clinical Benefit with Addition of Nebulized Aviptadil in Critically Ill Patients with COVID-19 01-Apr-2022 / 07:00 CET/CEST Release of an ad...

EQS-Adhoc: Relief Therapeutics Holding SA: Relief Reports that its U.S. Collaboration Partner has Announced that the I-SPY COVID Trial Suggests No Clinical Benefit with Addition of Nebulized Aviptadil in Critically Ill Patients with COVID-19 - Vimarsana News

EQS-Adhoc: Relief Therapeutics Holding SA: Relief Reports that its U.S. Collaboration Partner has Announced that the I-SPY COVID Trial Suggests No Clinical Benefit with Addition of Nebulized Aviptadil in Critically Ill Patients with COVID-19

Relief Therapeutics Holding SA / Key word(s): Study Relief Reports that its U.S. Collaboration Partner has Announced that the I-SPY COVID Trial Suggests No Clinical Benefit with Addition of Nebulized